Van ECK Associates Corp reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 35.5% in the 3rd quarter, according to the company in its most recent 13F filing with the ...

A $1000 investment made in November 2014 would be worth $6,540.57, or a gain of 554.06%, as of November 8, 2024, according to our calculations. This return excludes dividends but includes price ...

Verdence Capital Advisors LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.9% in the third quarter, according to the company in its most recent 13F ...

Analyst Brendan Smith of TD Cowen maintained a Buy rating on BioLife Solutions (BLFS – Research Report), boosting the price target to ...

In a report released today, Brendan Smith from TD Cowen reiterated a Buy rating on 908 Devices (MASS – Research Report). The ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Short interest in Halozyme Therapeutics Inc (NASDAQ:HALO) increased during the last reporting period, rising from 9.64M to 9.85M. This put 10.54% of the company's publicly available shares short.

In June, PanGen, a raw material producer of human hyaluronidase, signed an entrustment contract with Huonslab, a Huons ...

Thursday, November 7, 2024 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com ...

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...